论文部分内容阅读
目的:分析急诊治疗急性心肌梗塞应用尿激酶静脉溶栓的治疗效果。方法:选取2015年9月-2016年9月期间,我院收治的52例急性心肌梗塞患者作为研究对象,其中男33例,女19例,患者均采用尿激酶静脉溶栓治疗,统计患者的检查化验结果,包括心电图、心肌酶等,及心肌梗死的再通情况,观察患者的治疗副作用的发生情况。结果:52例患者经过溶栓后,再通成功的有39例,溶栓再通成功率为75.0%,并且溶栓再通成功率与发病时间具有一定关系,随着发病时间增加,溶栓成功率逐渐减小。该疗法溶栓效果较好,无严重副作用,安全性较高。结论:急诊时治疗急性心肌梗塞时,应用尿激酶静脉溶栓的治疗效果较好,并且安全性较高,值得推广。
Objective: To analyze the therapeutic effect of intravenous thrombolytic therapy with urokinase in emergency treatment of acute myocardial infarction. Methods: From September 2015 to September 2016, 52 acute myocardial infarction patients admitted to our hospital were selected as the study subjects, including 33 males and 19 females. All patients were treated with intravenous thrombolytic therapy of urokinase. Check the test results, including ECG, myocardial enzymes, and recanalization of myocardial infarction observed the incidence of side effects of treatment of patients. Results: The success rate of thrombolysis recanalization in 52 patients succeeded after thrombolytic therapy was 39 and the success rate of thrombolysis recanalization was 75.0%. The success rate of thrombolysis recanalization was related to the time of onset. With the increase of the onset time, thrombolysis Success rate gradually decreased. The thrombolytic effect of the therapy is better, no serious side effects, higher safety. Conclusion: Emergency treatment of acute myocardial infarction, the application of intravenous thrombolytic effect of urokinase is better, and the safety is high, it is worth promoting.